Hip osteoarthritis Musculoskeletal Diseases Coxarthrosis [arthrosis of hip]
Conditions
Interventions
The participants will be randomly allocated to the following two groups:
Group 1: Kenalog® (triamcinolone) 80 mg intraarticular injection into hip joint, used once on Day 1.
Group 2: Hyaluronic acid
Sponsors
Dorset County Hospital NHS Foundation Trust (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Clinical and radiological diagnosis of osteoarthritis (primary or secondary) 2. Both males and females, age over 16 years 3. Ability to understand the process and consent
Exclusion criteria
Exclusion criteria: 1. Presence of any active infection elsewhere 2. History of previous hip joint infection 3. Patients with a diagnosis of avascular necrosis of femoral head 4. Rheumatoid arthritis 5. Underlying joint replacement
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The following will be assessed at 6 weeks, 3 and 6 months: 1. Visual Analogue Scale (VAS) for pain 2. Oxford hip score for function | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Duration of pain relief 2. Any complications, followed-up for 6 months | — |
Countries
United Kingdom
Outcome results
None listed